Nurix Therapeutics (NRIX) Short-term Investments (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Short-term Investments data on file, last reported at $375.8 million in Q2 2026.

• On a quarterly basis, Short-term Investments fell 6.39% year-over-year to $375.8 million in Q2 2026; TTM through May 2026 was $375.8 million, a 6.39% decrease from a year earlier, with the FY2025 full-year figure at $346.0 million, down 30.75% from the prior year.
• Short-term Investments for Q2 2026 stood at $375.8 million, down from $469.5 million in the prior quarter.
• Over the last five years, Short-term Investments for NRIX reached as high as $499.6 million in Q4 2024 and fell as low as $183.2 million in Q1 2022.
• Historically, Short-term Investments has averaged $315.7 million across 5 years, with a median of $311.6 million in 2022.
• On a YoY basis, Short-term Investments climbed as much as 143.98% in 2025 and fell as far as 30.75% in 2025.
• Year by year, Short-term Investments stood at $244.7 million in 2022, then declined by 4.65% to $233.3 million in 2023, then soared by 114.16% to $499.6 million in 2024, then sank by 30.75% to $346.0 million in 2025, then rose by 8.63% to $375.8 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $375.8 million in Q2 2026, $469.5 million in Q1 2026, and $346.0 million in Q4 2025.